Skip to content

Clinical effects and safety of methylene blue for the treatment of lumbar facet joint syndrome: a prospective, randomized controlled clinical trial

Clinical effects and safety of methylene blue for the treatment of lumbar facet joint syndrome: a prospective, randomized controlled clinical triall

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034132
Enrollment
Unknown
Registered
2020-06-25
Start date
2020-06-01
Completion date
Unknown
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar facet joint syndrome

Interventions

Group 1:Methylene blue lumbar facet joint capsule injection
Group 2:Debauterine capsule injection

Sponsors

Shanghai Oriental Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Older than 18 years old; 2. Patients with chronic back or lower extremity pain longer than 3 months; 3. Those patients who have low back pain with or without radiation pain in the buttocks indicating small joint syndrome (the pain of stretching or bending the spine to the affected side is aggravated; the pain of sitting, climbing the steps and holding a posture for a long time is aggravated); 4. Patients who fail in conservative treatment (physical therapy, drug therapy, etc.); 5. The patient or his family members sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of lumbar trauma or lumbar surgery; 2. Patients with abnormal lumbar imaging findings but no symptoms of low back pain; 3. Low back pain caused by other other diseases, such as lumbar deformity, lumbar tuberculosis or tumor, intervertebral disc lesions, spinal canal lesions, radiation pain from other parts, cardiovascular diseases, rheumatic immune system diseases, etc.; 4. Patients who received systemic steroid therapy within 1 month or intracapsular steroid injection within 6 months; 5. Pregnant or lactating women, patients with psychosis and patients with other major diseases; 6. Patients with poor compliance or lost follow-up.

Design outcomes

Primary

MeasureTime frame
Numeric Rating Scale;

Secondary

MeasureTime frame
Oswestry disability index;The Chinese version of the Pittsburgh Sleep Quality Index;Patient Health Questionnaire-9;Rescue Medication;Adverse complication;Effective Treatment Rate;

Countries

China

Contacts

Public ContactYu Xiuqin

Shanghai Oriental Hospital

xiuqin020112@163.com+86 19821228335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026